The natural history of incidentally detected small renal masses

Cancer ◽  
2004 ◽  
Vol 101 (3) ◽  
pp. 650-650 ◽  
Author(s):  
Andrew Renshaw
Cancer ◽  
2004 ◽  
Vol 100 (4) ◽  
pp. 738-745 ◽  
Author(s):  
Alessandro Volpe ◽  
Tony Panzarella ◽  
Ricardo A. Rendon ◽  
Masoom A. Haider ◽  
Filippos I. Kondylis ◽  
...  

2000 ◽  
pp. 1143-1147 ◽  
Author(s):  
RICARDO A. RENDON ◽  
NIR STANIETZKY ◽  
TONY PANZARELLA ◽  
MICHAEL ROBINETTE ◽  
LAWRENCE H. KLOTZ ◽  
...  

2007 ◽  
Vol 7 ◽  
pp. 860-868 ◽  
Author(s):  
Alessandro Volpe

Incidentally detected, small renal masses (SRMs) have been increasing significantly in recent years due to the widespread use of improved cross-sectional imaging. A significant number of incidental SRMs are diagnosed in elderly patients who are more likely to undergo imaging for other medical issues. The natural history of SRMs has not been historically well understood because most masses are surgically removed soon after diagnosis.Several reports of surveillance of SRMs have been published in the last few years. When followed conservatively with serial imaging, SRMs have variable growth rates with an average of 0.28 cm/year, according to a recent meta-analysis. Larger series with longer follow-up are needed, but a significant number of small tumors seem to have an indolent behavior with a slow growth rate and a limited tendency to progress. The standard of care for enhancing SRMs is surgery. Up to one-third of surgically removed, <4-cm tumors are histologically benign. The outcomes of current surgical treatment of histologically confirmed, <4-cm, renal cell carcinomas are excellent, but this has not led to a decrease in mortality. Based on these considerations and on the available data on the natural history of SRMs, it seems reasonable to consider that we may be overtreating these lesions. This is especially true for elderly or unfit patients who have a decreased life expectancy. In these selected patients and in patients who refuse active treatment, it seems reasonable to propose an initial period of active surveillance for incidental SRMs, with delayed intervention for those tumors that will exhibit fast growth during follow-up. Percutaneous needle biopsies of renal tumors can be safely performed with the use of modern techniques and have the potential to characterize SRMs at histologically diagnosis, thereby allowing a better selection of the conservative or active treatment that is best suited for each individual patient.


2018 ◽  
Author(s):  
Keith A Lawson ◽  
Antonio Finelli

The rise in incidentally discovered enhancing solid renal tumors has spurred the development of new approaches to managing this unique clinical entity known as the small renal mass (SRM). These approaches are grounded on a better understanding of the natural history of SRM, with the goal to reduce the morbidity associated with their management and avoid overtreatment. In this chapter, we review the body of evidence pertaining to the classification and clinical management of SRMs with respect to diagnosis, treatment, and follow-up. In addition, we discuss the controversies and active areas of development for this rapidly evolving field that strides towards a precision medicine paradigm.  This review contains 6 figures, 6 tables and 63 references Keywords: Small renal mass, renal cell carcinoma, radical nephrectomy, renal tumor biopsy, active surveillance, natural history, oncocytoma, robotic surgery, partial nephrectomy


2007 ◽  
Vol 177 (4S) ◽  
pp. 169-170 ◽  
Author(s):  
Kamal Mattar ◽  
Julian Azuero ◽  
Ricardo Rendon ◽  
Christopher Morash ◽  
D. Robert Siemens ◽  
...  

2018 ◽  
Author(s):  
Keith A Lawson ◽  
Antonio Finelli

The rise in incidentally discovered enhancing solid renal tumors has spurred the development of new approaches to managing this unique clinical entity known as the small renal mass (SRM). These approaches are grounded on a better understanding of the natural history of SRM, with the goal to reduce the morbidity associated with their management and avoid overtreatment. In this chapter, we review the body of evidence pertaining to the classification and clinical management of SRMs with respect to diagnosis, treatment, and follow-up. In addition, we discuss the controversies and active areas of development for this rapidly evolving field that strides towards a precision medicine paradigm.  This review contains 6 figures, 6 tables and 63 references Keywords: Small renal mass, renal cell carcinoma, radical nephrectomy, renal tumor biopsy, active surveillance, natural history, oncocytoma, robotic surgery, partial nephrectomy


2000 ◽  
Vol 164 (4) ◽  
pp. 1143-1147 ◽  
Author(s):  
RICARDO A. RENDON ◽  
NIR STANIETZKY ◽  
TONY PANZARELLA ◽  
MICHAEL ROBINETTE ◽  
LAWRENCE H. KLOTZ ◽  
...  

2018 ◽  
Vol 13 (8) ◽  
Author(s):  
Naji J. Touma ◽  
Gregory W. Hosier ◽  
Michael A. Di Lena ◽  
Robert J. Leslie ◽  
Louisa Ho ◽  
...  

Introduction: The natural history of small renal masses has been well defined, leading to the recommendation of active surveillance in some patients with limited life expectancy. However, this information is less clear for large renal masses (LRM), leading to ambiguity for management in the older, comorbid patient. The objective of this study was to define the natural history, including the growth rate and metastatic risk, of LRM in order to better counsel patients regarding active surveillance.Methods: This was a retrospective review of patients with solid renal masses >4 cm that had repeated imaging identified from an institutional imaging database. Patient comorbidities and outcomes were obtained through retrospective chart analysis. Outcomes assessed included tumour growth and metastatic rates, as well as cancer-specific (CSS) and overall survival (OS) usimg Kaplan-Meier methodology.Results: We identified 69 patients between 2005 and 2016 who met the inclusion criteria. Mean age at study entry was 75.5 years; mean tumour maximal dimension at study entry was 5.6 cm. CSS was 83% and OS 63% for patients presenting without metastasis, with a mean followup of 57.5 months. The mean growth rate of those that developed metastasis during followup (n=15) was 0.98 cm/year (95% confidence interval [CI] 0.33‒1.63) as compared to those that did not develop metastasis (n=46), with a growth rate of 0.67 cm/year (95% CI 0.34‒1) (non-significant). Seven patients had evidence of metastasis at the baseline imaging of their LRM and had subsequent growth rate of 1.47 cm/year (95% CI 0.37‒2.57) (non-significant).Conclusions: Compared to small renal masses, LRM are associated with higher metastasis rates and lower CSS and more rapid growth rates. Selection criteria for recommending observation of LRM in older, comorbid patients should be more conservative than for small renal masses.


2021 ◽  
Vol 206 (Supplement 3) ◽  
Author(s):  
Joseph Cheaib ◽  
Sunil Patel ◽  
Ridwan Alam ◽  
Meredith Metcalf ◽  
Dmitry Enikeev ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document